Literature DB >> 7255899

A new tick cell line derived from Boophilus microplus.

P J Holman, N C Ronald.   

Abstract

The Boophilus microplus IX tick cell line was developed from a primary embryonic cell culture derived from eggs six to nine days old. The cell line has been in culture since March 1979 and is currently maintained at 32 degrees C in medium consisting of equal parts of minimum essential medium an Leibovitz 15 medium supplemented with 20 per cent fetal bovine serum, 10 per cent tryptose phosphate broth and 0.1 per cent plasma albumin. A split ratio of 1:2 has been used for all subcultures and the cell line is now in its 26th passage. The cells are predominantly epithelial-like and of the male diploid chromosome number 21.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7255899

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  4 in total

Review 1.  Tick cell lines for study of Crimean-Congo hemorrhagic fever virus and other arboviruses.

Authors:  Lesley Bell-Sakyi; Alain Kohl; Dennis A Bente; John K Fazakerley
Journal:  Vector Borne Zoonotic Dis       Date:  2011-09-28       Impact factor: 2.133

2.  Cellular and molecular characterization of an embryonic cell line (BME26) from the tick Rhipicephalus (Boophilus) microplus.

Authors:  Eliane Esteves; Flavio A Lara; Daniel M Lorenzini; Gustavo H N Costa; Aline H Fukuzawa; Luis N Pressinotti; José Roberto M C Silva; Jesus A Ferro; Timothy J Kurtti; Ulrike G Munderloh; Sirlei Daffre
Journal:  Insect Biochem Mol Biol       Date:  2008-02-09       Impact factor: 4.714

3.  Formulation of medium for tick cell culture.

Authors:  U G Munderloh; T J Kurtti
Journal:  Exp Appl Acarol       Date:  1989-08       Impact factor: 2.132

Review 4.  How relevant are in vitro culture models for study of tick-pathogen interactions?

Authors:  Cristiano Salata; Sara Moutailler; Houssam Attoui; Erich Zweygarth; Lygia Decker; Lesley Bell-Sakyi
Journal:  Pathog Glob Health       Date:  2021-06-30       Impact factor: 3.735

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.